Ribopro

Executive Summary

Ribopro is a Netherlands-based CDMO specializing in mRNA and RNA therapeutics, founded in 2020. The company offers end-to-end services from mRNA design and synthesis to R&D- and GMP-grade manufacturing, including lipid nanoparticle (LNP) formulation. Its proprietary RIBOSTEALTH™ and RIBOPERFECT™ technologies enable production of high-quality, high-performance mRNA for therapeutic and vaccine applications. As a private company with no disclosed funding, Ribopro is positioned to capitalize on the growing demand for mRNA manufacturing capabilities, particularly in the post-pandemic landscape where CDMOs are critical for scaling production.

Upcoming Catalysts (preview)

• TBDMajor partnership or contract with a vaccine developer60% success
• TBDSeries A financing round to expand GMP manufacturing capacity70% success
• TBDFDA or EMA approval of a customer's mRNA therapeutic using Ribopro's manufacturing services30% success